Trial Profile
An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2022
Price :
$35
*
At a glance
- Drugs Palupiprant (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Carcinoma; Rectal cancer
- Focus Adverse reactions
- Acronyms PRAER 1
- Sponsors Adlai Nortye; Eisai Co Ltd
- 27 Sep 2022 Results (n=48) of Population pharmacokinetic analysis( from two phase 1 studies NCT02540291 and NCT03152370) to characterize the pharmacokinetic profle of orally administered AN0025 after single and multipledoses in cancer patients presented at the 2022 American College of Clinical Pharmacology Annual Meeting
- 01 Oct 2021 Status changed from active, no longer recruiting to completed.
- 02 Jul 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Sep 2021.